Bukwang Pharmaceutical is partnering with Samsung Medical Center and mental wellness startup Bluesignum to develop a digital treatment aimed at improving social cognitive function in patients with schizophrenia. The collaboration seeks to combine the pharmaceutical company's expertise in central nervous system (CNS) treatments, clinical capabilities of the hospital, and digital technology to create new therapeutic options.
On October 15, Bukwang Pharmaceutical announced that it signed a memorandum of understanding (MOU) with Samsung Medical Center and Bluesignum for the joint development of the software medical device 'Affectus.'
Under this agreement, the three parties will collaborate throughout the entire development process of Affectus, including clinical development, product enhancement, regulatory approval, and application in clinical settings. Bukwang Pharmaceutical will contribute its expertise in CNS and commercialization experience, Samsung Medical Center will provide clinical research capabilities, and Bluesignum will offer digital technology and product development expertise.
Affectus is a software medical device currently under development, aimed at enhancing social cognitive function in patients with schizophrenia. It is designed to support patients' reintegration into daily life and society through digital-based social cognitive training. An exploratory clinical trial is currently underway at Samsung Medical Center.
The institutions plan to continue their collaboration to enhance the clinical applicability of Affectus and to develop it into a new treatment option for schizophrenia.
Lee Jae-young, CEO of Bukwang Pharmaceutical, stated, "We will work together to develop treatment options that benefit patients based on Bukwang Pharmaceutical's expertise in the CNS field."
Meanwhile, Bukwang Pharmaceutical became the largest shareholder of Korea Union Pharmaceutical by investing 30 billion won in new shares during its rehabilitation process in May. Recently, Bukwang Pharmaceutical changed the name of the acquired Korea Union Pharmaceutical to 'Bukwang Unipharma' and has begun integrating production systems.
On October 15, Bukwang Pharmaceutical announced that it signed a memorandum of understanding (MOU) with Samsung Medical Center and Bluesignum for the joint development of the software medical device 'Affectus.'
Under this agreement, the three parties will collaborate throughout the entire development process of Affectus, including clinical development, product enhancement, regulatory approval, and application in clinical settings. Bukwang Pharmaceutical will contribute its expertise in CNS and commercialization experience, Samsung Medical Center will provide clinical research capabilities, and Bluesignum will offer digital technology and product development expertise.
Affectus is a software medical device currently under development, aimed at enhancing social cognitive function in patients with schizophrenia. It is designed to support patients' reintegration into daily life and society through digital-based social cognitive training. An exploratory clinical trial is currently underway at Samsung Medical Center.
The institutions plan to continue their collaboration to enhance the clinical applicability of Affectus and to develop it into a new treatment option for schizophrenia.
Lee Jae-young, CEO of Bukwang Pharmaceutical, stated, "We will work together to develop treatment options that benefit patients based on Bukwang Pharmaceutical's expertise in the CNS field."
Meanwhile, Bukwang Pharmaceutical became the largest shareholder of Korea Union Pharmaceutical by investing 30 billion won in new shares during its rehabilitation process in May. Recently, Bukwang Pharmaceutical changed the name of the acquired Korea Union Pharmaceutical to 'Bukwang Unipharma' and has begun integrating production systems.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.